Condition: Microsatellite Stable Relapsed or Refractory Colorectal Cancer · Sponsor: Effector Therapeutics
This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerability of escalating doses of eFT508 in combination with a fixed dose of avelumab to determine the maximum tolerated dose (MTD) of eFT508 and to select a recommended dose for Part 2. The primary objective of Part 2 is to evaluate antitumor activity of eFT508 at the recommended dose in combination with avelumab or eFT508 monotherapy. Parts 1 and 2 will also evaluate pharmacokinetics (PK) and pharmacodynamics.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Scottsdale, Arizona, United States | — |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | — |
| Florida Cancer Specialists | Sarasota, Florida, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Kansas City Research Institute | Kansas City, Missouri, United States | — |
| Tennessee Oncology | Nashville, Tennessee, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03258398